Danaher Co. (NYSE:DHR) Position Lowered by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its stake in shares of Danaher Co. (NYSE:DHR) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 250,680 shares of the conglomerate’s stock after selling 2,061 shares during the period. Victory Capital Management Inc.’s holdings in Danaher were worth $57,992,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Cannell & Co. lifted its position in shares of Danaher by 0.9% during the fourth quarter. Cannell & Co. now owns 98,639 shares of the conglomerate’s stock worth $22,819,000 after purchasing an additional 865 shares during the last quarter. Phraction Management LLC lifted its holdings in Danaher by 24.6% in the fourth quarter. Phraction Management LLC now owns 36,993 shares of the conglomerate’s stock worth $8,558,000 after acquiring an additional 7,296 shares during the last quarter. PYA Waltman Capital LLC lifted its holdings in Danaher by 9.4% in the fourth quarter. PYA Waltman Capital LLC now owns 29,494 shares of the conglomerate’s stock worth $6,823,000 after acquiring an additional 2,524 shares during the last quarter. Hexagon Capital Partners LLC lifted its holdings in Danaher by 5.0% in the fourth quarter. Hexagon Capital Partners LLC now owns 1,211 shares of the conglomerate’s stock worth $280,000 after acquiring an additional 58 shares during the last quarter. Finally, Hartford Funds Management Co LLC lifted its holdings in Danaher by 5.4% in the fourth quarter. Hartford Funds Management Co LLC now owns 1,484 shares of the conglomerate’s stock worth $343,000 after acquiring an additional 76 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,273 shares of company stock worth $26,813,819. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

NYSE DHR opened at $248.38 on Friday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The firm has a market capitalization of $183.97 billion, a PE ratio of 42.10, a P/E/G ratio of 3.82 and a beta of 0.83. The company’s 50 day simple moving average is $248.48 and its 200 day simple moving average is $232.27.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same quarter last year, the business earned $2.36 earnings per share. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. As a group, equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analysts Set New Price Targets

DHR has been the topic of a number of recent research reports. Raymond James raised their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Barclays raised their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Citigroup raised their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Finally, TD Cowen raised their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.31.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.